Tucidinostat (Chidamide)

Catalog No.S8567 Synonyms: HBI-8000, CS-055

For research use only.

Tucidinostat (Chidamide, HBI-8000, CS-055) is a low nanomolar inhibitor of HDAC1, 2, 3, and 10, the HDAC isotypes well documented to be associated with the malignant phenotype with IC50 values of 95, 160, 67, 78 nM for HDAC1, 2, 3, 10 respectively.

Tucidinostat (Chidamide) Chemical Structure

CAS No. 1616493-44-7

Selleck's Tucidinostat (Chidamide) has been cited by 12 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Other HDAC Products

Biological Activity

Description Tucidinostat (Chidamide, HBI-8000, CS-055) is a low nanomolar inhibitor of HDAC1, 2, 3, and 10, the HDAC isotypes well documented to be associated with the malignant phenotype with IC50 values of 95, 160, 67, 78 nM for HDAC1, 2, 3, 10 respectively.
Targets
HDAC3 [1]
(Cell-free)
HDAC10 [1]
(Cell-free)
HDAC1 [1]
(Cell-free)
HDAC2 [1]
(Cell-free)
67 nM 78 nM 95 nM 160 nM
In vitro

Chidamide inhibits class I HDACs 1-3, as well as class IIb HDAC10, at low nanomolar concentrations. Chidamide significantly induces histone H3 acetylation in both HeLa human cervical adenocarcinoma cells and human PBMC. Cell growth inhibition studies performed with 18 human-derived tumor cell lines demonstrate that chidamide and MS-275 similarly inhibit the in vitro growth of most, but not all, tumor cells in the low micromolar concentration range. However, chidamide, and to a lesser extent MS-275, is significantly less toxic to normal cells from human fetal kidney (CCC-HEK) and liver (CCC-HEL), indicating a differential cytotoxic response of normal cells versus cancerous cells to chidamide[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 MYDGeY5kfGmxbjDhd5NigQ>? M4fFdVUhdWmwcx?= MnrFTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDISGFEOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{B2e2mwZzDibY91cW67bHH0[YQhdHm|aX7lJFkh[WOndInsZZRm\CCqaYP0c45mKEh|IDixJJRwKDJzIILld4llfWW|KTDhd{B{fWK|dILheIUhcW6ldXLheIVlKG[xcjC1JI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJI1m[XO3cnXkJIFnfGW{IE[wJI1qNCCLQ{WwJF0hOC5zMUKg{txONg>? NHjyeIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pyd-Mki4N|U4QTd:L3G+
EBC1 NF3VU2pCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MlTOO|IhcHK| M1nlOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRVLDNUBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMj65JO69VS5? NEW4bpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVc6Pyd-Mki4N|U4QTd:L3G+
HCT116 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NYfXfXllPzJiaILz M3i4XmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTC3Mlgh|ryPLh?= NVr3VXk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N|U4QTdpPkK4PFM2Pzl5PD;hQi=>
HL60 M2O1Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFLyb5Q1QCCqcoO= Mo\KS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGw3OCClZXzsd{BqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHMhdWW2aH;kMEBIUTVyIE2gNE41KM7:TT6= NHjUcFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
Jurkat Mn7rS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Moe0OFghcHK| NWi1epRHT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUnW{a3H0JINmdGy|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WUzDt[ZRpd2RuIFfJOVAhRSBzLkWg{txONg>? MoXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
hematopoietic malignant cells M1fBTGN6fG:2b4jpZ4l1gSCjc4PhfS=> M{Dmb2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIhmdWG2b4DvbYV1cWNibXHsbYdv[W62IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wLDDHTVUxKD1iMT64OkDPxE1w NIi5PIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS M1vCNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWi0PEBpenN? NWP5XGJ2T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXTKRUzDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hOiEQvF2u MkP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
HepG2 MV;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVz3ZYt3PDhiaILz NXWxcHFGT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUGWyR{KgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSVIH3leIhw\CxiR1m1NEA:KDRizszNMi=> MnGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
LNCAP M{LmW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{jySFQ5KGi{cx?= MmnzS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUG5ESVBiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFQh|ryPLh?= MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
Raji MmHYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV3zbFNQPDhiaILz NYXkfnU4T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWmGsaTDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hPCEQvF2u NWDwdVNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
MCF7 NGqwNXVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NET0emk1QCCqcoO= NHTl[XhIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOS0Z5IHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUA2KM7:TT6= M1\wPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
28SC NXXZ[oNUT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{G2elQ5KGi{cx?= MXrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjCyPHNEKGOnbHzzJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UV{Bu\XSqb3SsJGdKPTBiPTC1Mlgh|ryPLh?= M1nDSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
PANC1 M2rNVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{fT[FQ5KGi{cx?= MlTMS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGFPSzFiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFYvOyEQvF2u MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
human solid tumor cells NELYW3FEgXSxdH;4bYNqfHliYYPzZZk> MnnDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gd49tcWRidIXtc5Ih[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44tKEeLNUCgQUA3NjZ3IN88UU4> NEPKbHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
HeLa MlHGSpVv[3Srb36gZZN{[Xl? NWPwNWxVOTBibXnudy=> M1XRemlvcGmkaYTpc44hd2ZiSFTBR{Bmdnq7bXH0bYMh[WO2aY\peJkhcW5iaIXtZY4hUGWOYTDj[YxteyCrbnP1ZoF1\WRiZn;yJFExKG2rboOgbY4heHKnc3XuZ4Uhd2Zic4Xid5Rz[XSnIHL5JINwdG:{aX3leJJq[yCjY4Tpeol1gSCjc4PhfUwhUUN3MDC9JFcvOiEQvF2u M2qxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
MDA-MB-231 MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{ewVVQ5KGi{cx?= MXLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WUzDt[ZRpd2RuIFfJOVAhRSB5Lkmg{txONg>? NHHQ[Gk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
SMMC7721 NWLmXFQ3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUnFRmtYPDhiaILz M3nTbmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNOVUN5N{KxJINmdGy|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WUzDt[ZRpd2RuIFfJOVAhRSBzNjFOwG0v MoP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
DU145 MoPSS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4fXZlQ5KGi{cx?= M4TWUGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGRWOTR3IHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUAzPSEQvF2u NVXSOog6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
HeLa MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV2yVnlxPDhiaILz MV3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDI[WxiKGOnbHzzJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UV{Bu\XSqb3SsJGdKPTBiPTC0NEDPxE1w NWnKboxIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
U2OS MlH4SpVv[3Srb36gZZN{[Xl? NVjmeWhVOSC3TR?= NIjEd4QzPCCqcoO= MXTBZ5RqfmG2aX;uJI9nKFCSQWLHJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKGi3bXHuJHUzV1NiY3XscJMh[XRiMTD1UUBqdiCycnXz[Y5k\SCxZjCxNEB2VSC{b4Pp[4xqfGG8b37lJIlv[3WkYYTl[EBnd3JiMkSgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> M4P0cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
U2OS M1LPcWZ2dmO2aX;uJIF{e2G7 MXKxJJVO MmfoNlQhcHK| Ml7ZRYN1cX[jdHnvckBw\iCHUnLleIEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwIIDy[ZNmdmOnIH;mJFAvODFidV2gSVIhcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS NVPU[pdKTnWwY4Tpc44h[XO|YYm= Ml[2NUB2VQ>? NW\ZOplyOjRiaILz Mn3HRYN1cX[jdHnvckBw\iCpbIXsZ49kd3K2aXPvbYQhemWlZYD0c5IhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwIIDy[ZNmdmOnIH;mJFAvOSC3TTDk[ZhidWW2aHHzc45mKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NH\LcHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS NV3ke5RyTnWwY4Tpc44h[XO|YYm= MnvhNUB2VQ>? M1faS|I1KGi{cx?= M1rQT2FkfGm4YYTpc44hd2ZiRWLhcJBp[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDoeY1idiCXMl;TJINmdGy|IHH0JFEhfU1iaX6gdJJme2WwY3Wgc4YhOC5yMTD1UUBGOiCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
U2OS MWnGeY5kfGmxbjDhd5NigQ>? NFvBblIyKHWP M2q5fVI1KGi{cx?= NYSzV2h{SWO2aY\heIlwdiCxZjDncJVt[2:lb4L0bYNwcWRicnXj[ZB1d3JiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gbJVu[W5iVULPV{Bk\WyuczDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?= MkXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
U2OS M1rSNGZ2dmO2aX;uJIF{e2G7 M3XSOlEhfU1? MVmyOEBpenN? M3XjfGFkfGm4YYTpc44hd2ZiUGDBVmchMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? M4\vXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
U2OS MnTySpVv[3Srb36gZZN{[Xl? MmLxNUB2VQ>? NX:2ZYdKOjRiaILz NES5U2NC[3SrdnH0bY9vKG:oIFXSZYxxcGFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gbJVu[W5iVULPV{Bk\WyuczDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?= M3exSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
U2OS M3jteGZ2dmO2aX;uJIF{e2G7 NV;uOpZSOSC3TR?= NGrYVI8zPCCqcoO= MYLBZ5RqfmG2aX;uJI9nKEWUYnX0ZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCqdX3hckBWOk:VIHPlcIx{KGG2IEGgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 NVHxXldpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
Assay
Methods Test Index PMID
Western blot PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; p-EGFR / EGFR / p-STAT3 / STAT3 / p-AKT / AKT / p-AMPK / MAPK ; Ace-H3K18 / Ace-H3K9 / Ac-H4K8 ; Mcl-1 / Myc / Bcl-xl / p21 / p27 / CDK6 / CDK4 / Cyclin D2 ; HDAC1 / HDAC2 / HDAC3 / acetyl-H3 / acetyl-H4 30854137 29773595 31289512
Growth inhibition assay Cell viability 29100410
In vivo In HCT-8 colorectal carcinoma mice xenografts, Chidamide shows in vivo antitumor activity. Chidamide in the dose range of 12.5-50 mg/kg dose-dependently reduces tumor size and tumor weight, and the dose of 50 mg/kg produces similar or greater efficacy compared with the control drugs 5-fluorouracil(5-FU, 20 mg/kg) and MS-275 (25 mg/kg, which was reported as the maximum tolerated dose in xenograft models). However, chidamide is well-tolerated at the above doses in the tumor-bearing animals, whereas the control drugs cause significant weight loss[1].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: PBMC effector cells
  • Concentrations: 0-400 nM
  • Incubation Time: 0-400 nM
  • Method:

    Isolated PBMC effector cells are seeded into 6-well plates (6 x 106 cells/well) and treated with chidamide at different concentrations (0-400 nM) for different times (24-72 h).

Animal Research:

[1]

  • Animal Models: Athymic nude mice (BALB/c-nu)
  • Dosages: 12.5-50 mg/kg
  • Administration: oral

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.

30mg/mL

Chemical Information

Molecular Weight 390.41
Formula

C22H19FN4O2

CAS No. 1616493-44-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=CN=C1)C=CC(=O)NCC2=CC=C(C=C2)C(=O)NC3=C(C=C(C=C3)F)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05141357 Not yet recruiting Drug: HBI-8000 in combination with pembrolizumab Non Small Cell Lung Cancer HUYABIO International LLC. December 2021 Phase 2
NCT04994210 Not yet recruiting Drug: Sintilimab|Drug: Chidamide Safety and Efficacy Sun Yat-sen University September 1 2021 Phase 2
NCT05140616 Recruiting Drug: Chidamide Safety and Efficacy The First Affiliated Hospital of Soochow University May 31 2021 Phase 1|Phase 2
NCT04651127 Recruiting Drug: Toripalimab + Chidamide Cervical Cancer|Cervix Cancer|Cervix Neoplasm Sun Yat-sen University November 9 2020 Phase 1|Phase 2
NCT03820596 Recruiting Drug: Sintilimab|Drug: Chidamide Safety and Efficacy Huiqiang Huang|Sun Yat-sen University March 29 2019 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Tucidinostat (Chidamide) | Tucidinostat (Chidamide) supplier | purchase Tucidinostat (Chidamide) | Tucidinostat (Chidamide) cost | Tucidinostat (Chidamide) manufacturer | order Tucidinostat (Chidamide) | Tucidinostat (Chidamide) distributor